Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

VSTM – Verastem, Inc.

Verastem, Inc.
VSTM
$9.08
Name : Verastem, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $558,831,296.00
EPSttm : -3.5
finviz dynamic chart for VSTM
Verastem, Inc.
$9.08
5.21%
$0.45

Float Short %

30.16

Margin Of Safety %

Put/Call OI Ratio

0.19

EPS Next Q Diff

-0.22

EPS Last/This Y

1.23

EPS This/Next Y

0.49

Price

9.07

Target Price

15.12

Analyst Recom

1

Performance Q

21.39

Relative Volume

1.79

Beta

0.88

Ticker: VSTM




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25VSTM6.140.280.927085
2025-07-28VSTM6.030.370.037813
2025-07-29VSTM6.30.370.007903
2025-07-30VSTM6.240.360.517965
2025-07-31VSTM6.190.400.008742
2025-08-01VSTM6.090.400.188777
2025-08-04VSTM6.010.390.018829
2025-08-05VSTM5.970.390.008840
2025-08-06VSTM5.720.390.018875
2025-08-07VSTM5.630.391.508957
2025-08-08VSTM6.740.390.059098
2025-08-11VSTM7.690.330.0110690
2025-08-12VSTM8.20.111.0329156
2025-08-13VSTM8.020.200.0132763
2025-08-14VSTM7.720.240.1328227
2025-08-15VSTM8.230.250.0128245
2025-08-18VSTM7.970.140.4720291
2025-08-19VSTM7.790.178.9821810
2025-08-20VSTM8.310.190.3422245
2025-08-21VSTM8.620.190.1322381
2025-08-22VSTM9.070.190.0122192
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25VSTM6.14-22.1- -2.60
2025-07-28VSTM6.01-22.1- -2.60
2025-07-29VSTM6.29-22.1- -2.60
2025-07-30VSTM6.23-22.1- -2.60
2025-07-31VSTM6.17-22.1- -2.60
2025-08-01VSTM6.08-22.1- -2.60
2025-08-04VSTM6.01-22.1- -2.60
2025-08-05VSTM5.97-22.1- -2.60
2025-08-06VSTM5.71-22.1- -2.60
2025-08-07VSTM5.62-22.1- -2.60
2025-08-08VSTM6.74-22.1- -2.60
2025-08-11VSTM7.69-22.1- -2.60
2025-08-12VSTM8.2127.3- -2.60
2025-08-13VSTM8.0227.3- -2.60
2025-08-14VSTM7.7227.3- -2.60
2025-08-15VSTM8.2327.3- -2.55
2025-08-18VSTM7.9727.3- -2.55
2025-08-19VSTM7.7927.3- -2.55
2025-08-20VSTM8.3127.3- -2.55
2025-08-21VSTM8.6327.3- -2.55
2025-08-22VSTM9.0730.3- -2.44
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25VSTM-1.5616.2737.03
2025-07-28VSTM-1.5616.1637.03
2025-07-29VSTM-1.5616.1637.03
2025-07-30VSTM-1.5616.1637.03
2025-07-31VSTM-1.5616.1637.03
2025-08-01VSTM-1.5616.1637.03
2025-08-04VSTM-1.5652.1237.03
2025-08-05VSTM-1.5652.1237.03
2025-08-06VSTM-1.5552.1237.03
2025-08-07VSTM-1.5752.1237.03
2025-08-08VSTM-1.5752.1237.03
2025-08-11VSTM-1.4034.1537.03
2025-08-12VSTM-1.4034.1531.13
2025-08-13VSTM-1.4034.1531.13
2025-08-14VSTM-1.4034.1531.13
2025-08-15VSTM-1.4034.1531.13
2025-08-18VSTM-1.1639.3431.97
2025-08-19VSTM-1.1639.3430.16
2025-08-20VSTM-1.8939.3430.16
2025-08-21VSTM-1.8939.3430.16
2025-08-22VSTM-1.8939.3430.16
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.39

Avg. EPS Est. Current Quarter

-0.61

Avg. EPS Est. Next Quarter

-0.61

Insider Transactions

-1.89

Institutional Transactions

39.34

Beta

0.88

Average Sales Estimate Current Quarter

5

Average Sales Estimate Next Quarter

10

Fair Value

Quality Score

10

Growth Score

32

Sentiment Score

85

Actual DrawDown %

84.7

Max Drawdown 5-Year %

-96.2

Target Price

15.12

P/E

Forward P/E

PEG

P/S

261.14

P/B

15.49

P/Free Cash Flow

EPS

-3.51

Average EPS Est. Cur. Y​

-2.44

EPS Next Y. (Est.)

-1.94

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-7793.82

Relative Volume

1.79

Return on Equity vs Sector %

-486.6

Return on Equity vs Industry %

-473.7

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.16

EBIT Estimation

Verastem, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 78
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
stock quote shares VSTM – Verastem, Inc. Stock Price stock today
news today VSTM – Verastem, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VSTM – Verastem, Inc. yahoo finance google finance
stock history VSTM – Verastem, Inc. invest stock market
stock prices VSTM premarket after hours
ticker VSTM fair value insiders trading